Jupiter Orphan Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing therapies for rare diseases linked to single-gene deficiencies. Founded in the summer of 2015 and based in Jupiter, Florida, the company is led by Chairman & CEO Christer Rosén. JOT has defined five pipeline products, one of which is already in Phase II. The company recently secured financing totaling $2.5m. The financing includes a convertible note and an equity component, reflecting its current capital-raising activity amid ongoing clinical development.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2017